Howard S Hochster
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Background Human gastric cancer remains a diagnostic and therapeutic challenge worldwide. Improved prognostic biomarkers may support treatment planning, including surgery, neoadjuvant and adjuvant therapies. We offer a new liquid biopsy approach, integrated with esophagogastroduodenoscopy (EGD) to evaluate gastric fluid recovered from a large patient cohort (n=1,056 patients), demonstrating the value of a simple DNA concentration analysis to provide diagnostic support and prognosis in gastric cancer. Methods We performed an exploratory study to evaluate gastric fluid DNA (gfDNA) concentration in patients with normal gastric mucosa or diagnosed with peptic diseases, preneoplastic conditions, or cancer. Key variables including sex, gastric fluid pH, use of proton-pump inhibitors, tumor subtype, clinical stage, and disease outcomes were considered. Results gfDNA concentrations were significantly increased in gastric cancer versus all groups (mean 26.86 ng/µL; 95% CI: 20.05 to 33.79; p=3.61e-12) and as compared to non-malignant controls (normal mucosa and peptic diseases; mean 10.77 ng/µL; 95% CI: 9.23 to 12.33; p=9.55e-13), and preneoplastic conditions (mean 10.10 ng/µL; 95% CI: 7.59 to 12.60; p=1.10e-5). gfDNA concentrations were higher in advanced tumors (T3; mean 25.66 ng/µL; 95% CI: 19.46 to 31.85) compared to early-stage disease (T2 and below; mean 15.12 ng/µL; 95% CI: 9.73 to 20.50; p=5.97e-4). Our findings also suggest gfDNA prognostic value for gastric cancer diagnosed subjects. In this subset, patients with gfDNA concentrations >1.28 ng/µL showed longer progression-free survival (p=0.009), which correlated with increased tumor-infiltrating immune cells (p=0.001), remaining significant after adjusting for tumor stage (p=0.014). Conclusions While high gfDNA indicates gastric cancer in a general population and may contribute to disease management, its diagnostic clues should be integrated with further work up such as tissue biopsies, to ensure comprehensive and accurate clinical assessment. However, in patients with established gastric cancer, gfDNA is a potential prognostic marker, and subjects with high gfDNA content might paradoxically have better outcomes. The elevated presence of immune cell infiltrates—compared to those observed in peptic diseases and pre-neoplastic lesions (including their associated gastric cavity DNA shedding)—may serve as a critical missing link to resolve this empirical paradox.
Year:
2025
Triple therapy (ALX90, cetuximab, and pembrolizumab) activates human T cells and slows tumor growth of CRC307P colorectal cancer MSS PDX in HIS-BRGS mice. A, SGRs of CRC307P in HIS-BRGS mice among treatment groups: vehicle (V), ALX90 (A), cetuximab (C) + pembrolizumab (CP), ACP (ALX90 + cetuximab + pembrolizumab), LC, and ACP + LC. B, Human immune infiltration in CRC307P tumors in HIS-BRGS mice. Left, frequency of human immune (human CD45 + of mouse + human CD45 + ). Middle, number of human T cells. Right, frequency of CD8 + T cells among CD3 + cells. C, IFNγ+ and TNFα+ cytotoxic CD4 + and CD8 + tumor-infiltrating T cells. D, Immunophenotype correlation with tumor growth (SGR) among triple therapy (ACP, red), triple therapy following LC treatments (ACP + LC, purple), and all mice treated with triple therapy with or without LC (ACP ± LC, black). Statistics of linear correlation are provided; *, P P
Year:
2025
Pharmacodynamic analyses. A, Multiplex IHC of archival tumor tissue from one patient with disease progression and one patient with PR; B, Percent change (cycle 3 day 1 compared with baseline) in peripheral blood effector CD4 + (CD4 + CD3 + CD45RA − CD45RO − ) and CD8 + (CD8 + CD3 + CD45RA − CD45RO − ) T cells, granzyme B+ EOMES+ CD4 + (CD4 + CD3 + GrzB+EOMES+) and CD8 + (CD8 + CD3 + GrzB+EOMES+) T cells, and activated monocytes (CD11c + HLADR+CD16 + ) in patients with controlled disease (PR or stable disease) as best response compared with disease progression; ( C ) TCR diversity at baseline and after treatment (cycle 3 day 1 or cycle 4 day 1). GrzB, granzyme B. Statistics of linear correlation are provided; *, P
Year:
2025
Role of mouse myeloid cells in CRC307P-bearing HIS-BRGS mice treated with combinations of ALX90, cetuximab, pembrolizumab, and LC. A, Flow cytometric gating strategy for quantification of mouse (mCD45 + ) myeloid populations: PMNs (Ly6G+), M1 (CD38 + ) and M2 (CD206 + ) macrophages (MO: F4/80+), and expression of mouse MHC class I and class II. B, Quantification of human (left, CD11b + CD14 + , CD33 + , or CD11c + ) and mouse (right, mCD45 + ) myeloid populations in tumors of HIS-CRC307P-BRGS mice among treatment groups: vehicle (V), ALX90 (A), cetuximab (C) + pembrolizumab (CP), ACP (ALX90 + cetuximab + pembrolizumab), LC, and ACP + LC. C, Ratios of PMN/MO and M1/M2 of F4/80 macrophages among mouse myeloid cells. D, Correlation of mouse myeloid populations with tumor growth (SGR) among triple therapy (ACP, top) and triple therapy following LC treatments (ACP + LC, bottom). Statistics of linear correlation are provided; *, P P P
Year:
2025
Supplementary Figure S3. Triple therapy (ALX90, cetuximab, and pembrolizumab) activates human T cells and slows tumor growth of CRC307P CRC MSS PDX in HIS-BRGS mice with liposomal clodronate treatment (LC).
Year:
2025
Depth and duration of response by subject. A, Waterfall plot of best percent change in aggregate size of target lesions. B, Swimmer plot of duration of response. As of the data cutoff, subject 36-002 remained on study. In ( A ), subject 30-002 is not included due to a 35% decrease in target lesions but unequivocal progression in nontarget lesions. PI, principal investigator.
Year:
2025
Purpose: In this preclinical human immune system patient-derived xenograft (HIS-PDX) model and phase II clinical trial, we assessed evorpacept (anti-CD47 engineered fusion protein with inactive Fc), cetuximab, and pembrolizumab (triple therapy) in microsatellite-stable (MSS) colorectal cancer. Patients and Methods: HIS BALB/c-Rag2 null Il2rγ null Sirpα NOD mice with PDXs were treated with triple therapy or its components. Patients with refractory MSS colorectal cancer were treated with triple therapy in a safety run-in (stage 1) followed by expansion (stage 2, planned N = 42). The co-primary objectives were to determine the recommended dose of evorpacept and objective response rate (vs. historic control). Results: In HIS-PDX mice, triple therapy decreased the growth of MSS colorectal cancer tumors and increased tumor-infiltrating CD8 + T cells. Sixteen patients were treated on the clinical trial across two evorpacept dose levels: N = 12 in stage 1 and N = 4 in stage 2. Trial enrollment was terminated early because of safety concerns (one treatment-related grade 5 event each of hemophagocytic lymphohistiocytosis and cytokine release syndrome). Otherwise, the adverse event profile was as expected. Among all patients, the objective response rate was 6.3%; formal hypothesis testing was not performed. The disease control rate was 12.5%, the median progression-free survival was 2.3 months, and the median overall survival was 10.9 months. Blood- and tumor-based clinical trial correlative analyses identified innate and adaptive immune system activation. Conclusions: Whereas triple therapy demonstrated evidence of efficacy in refractory MSS colorectal cancer, safety concerns halted enrollment. Further investigation is necessary to determine the optimal use of CD47-targeted therapies in MSS colorectal cancer. Significance: Evorpacept, cetuximab, and pembrolizumab demonstrated antitumor activity in a preclinical HIS-PDX model and clinical trial in refractory MSS colorectal cancer; however, immune-related adverse events prompted early termination of study enrollment. Evidence of innate and adaptive antitumor immune activation was identified. The role of SIRPα/CD47 blockade in the treatment of MSS colorectal cancer needs to be further elucidated in future trials.
Year:
2025
Background Human gastric cancer remains a diagnostic and therapeutic challenge worldwide. Improved prognostic biomarkers may support treatment planning, including surgery, neoadjuvant and adjuvant therapies. We offer a new liquid biopsy approach, integrated with esophagogastroduodenoscopy (EGD) to evaluate gastric fluid recovered from a large patient cohort (n=1,056 patients), demonstrating the value of a simple DNA concentration analysis to provide diagnostic support and prognosis in gastric cancer. Methods We performed an exploratory study to evaluate gastric fluid DNA (gfDNA) concentration in patients with normal gastric mucosa or diagnosed with peptic diseases, preneoplastic conditions, or cancer. Key variables including sex, gastric fluid pH, use of proton-pump inhibitors, tumor subtype, clinical stage, and disease outcomes were considered. Results gfDNA concentrations were significantly increased in gastric cancer versus all groups (mean 26.86 ng/µL; 95% CI: 20.05 to 33.79; p=3.61e-12) and as compared to non-malignant controls (normal mucosa and peptic diseases; mean 10.77 ng/µL; 95% CI: 9.23 to 12.33; p=9.55e-13), and preneoplastic conditions (mean 10.10 ng/µL; 95% CI: 7.59 to 12.60; p=1.10e-5). gfDNA concentrations were higher in advanced tumors (T3; mean 25.66 ng/µL; 95% CI: 19.46 to 31.85) compared to early-stage disease (T2 and below; mean 15.12 ng/µL; 95% CI: 9.73 to 20.50; p=5.97e-4). Our findings also suggest gfDNA prognostic value for gastric cancer diagnosed subjects. In this subset, patients with gfDNA concentrations >1.28 ng/µL showed longer progression-free survival (p=0.009), which correlated with increased tumor-infiltrating immune cells (p=0.001), remaining significant after adjusting for tumor stage (p=0.014). Conclusions While high gfDNA indicates gastric cancer in a general population and may contribute to disease management, its diagnostic clues should be integrated with further work up such as tissue biopsies, to ensure comprehensive and accurate clinical assessment. However, in patients with established gastric cancer, gfDNA is a potential prognostic marker, and subjects with high gfDNA content might paradoxically have better outcomes. The elevated presence of immune cell infiltrates—compared to those observed in peptic diseases and pre-neoplastic lesions (including their associated gastric cavity DNA shedding)—may serve as a critical missing link to resolve this empirical paradox.
Year:
2025
PURPOSE Combined BRAF, MEK, and EGFR inhibition can induce clinical responses in BRAF-V600E-mutant colon cancer, but rapid resistance often occurs. METHODS We use serial monitoring of circulating tumor DNA cell-free plasma DNA (cfDNA) in a patient case study in addition to organoids derived from mouse models of BRAF-V600E-mutant intestinal cancer, which emulated the patient's mutational profile to assess drug treatment efficacy. RESULTS We demonstrate dynamic evolution of resistance to combined EGFR/BRAF/MEK inhibition in a pediatric patient with metastatic BRAF-V600E-mutant, mismatch repair-stable colon cancer. Initial resistance to targeted therapy was associated with development of MET amplification. Sequential treatment with chemotherapy and targeted therapy resulted in clearing of the resistant MET-amplified clone. Rechallenge with combined BRAF/EGFR inhibition resulted in clinical and radiographic response, demonstrating these treatments may be non–cross-resistant. Tumor organoids were used to model clinical findings and demonstrated effectiveness of combined targeted therapy and chemotherapy. CONCLUSION These findings suggest rational strategies for combining sequential chemotherapy and BRAF-/EGFR-directed therapy in BRAF-V600E-mutant colon cancer to prevent resistance and improve outcome. The data demonstrate rapid clonal dynamics in response to effective therapies in BRAF-V600E-mutant colon cancer that can be monitored by serial cfDNA analysis. Moreover, in mismatch repair-proficient BRAF-V600E-mutant colon cancers, combined EGFR and BRAF/MEK therapy is not cross-resistant with standard chemotherapy, suggesting new rational combination treatment strategies.
Year:
2024
Background Early studies showed promise of combined anti-epidermal growth factor receptor (EGFR) plus anti–vascular endothelial growth factor (VEGF) antibodies for advanced colorectal cancer (CRC), yet this was later rejected as toxic and ineffective in studies not selected for RAS status. We studied advanced KRAS wild-type CRC, as second-line treatment, using irinotecan-cetuximab with or without the anti-VEGF receptor antibody ramucirumab. Methods Patients with 1 prior regimen including fluoropyrimidine, oxaliplatin, and bevacizumab, with KRAS wild-type tumors were stratified by Eastern Cooperative Oncology Group Performance Score, time since last chemotherapy, and progression on oxaliplatin to irinotecan-cetuximab (IC) (180 mg/m2 and 500 mg/m2 every 2 weeks) vs modified ICR (irinotecan-cetuximab with ramucirumab 150 mg/m2 and 400 mg/m2 plus 6 mg/kg, respectively). A total of 102 patients were compared for progression-free survival (PFS) as primary endpoint (85% power for 70% improvement in median PFS from 4.5 to 7.65 months). Results Of the 102 enrolled, 44 treated with irinotecan-cetuximab and 45 with modified ramucirumab were evaluable. Median PFS was 6.0 months vs 9.2 months, respectively (hazard ratio = 0.75, P = .07; statistically significant by study design for P < .128). Response rate was 23% vs 36% (P = .27), and disease-control rate was 52% vs 73% (P = .05). Grade 3 or higher toxicity was equivalent. Overall survival was not significantly different at approximately 19 months. Conclusion Previous phase 3 trials without RAS genotyping rejected combining anti-epidermal growth factor receptor and anti-VEGF drugs. In this randomized multicenter phase 2 study for KRAS wild-type CRC (all previously bevacizumab treated), the addition of ramucirumab to irinotecan and cetuximab improved PFS and disease control rate, showing the combination is feasible and effective. Further, phase 3 trials with appropriate patient-selection are required. (NCT01079780)
Year:
2024
Year:
2023
Collaborators (15)
Junxiao Hu
Assistant Professor
University of Colorado Anschutz Medical Campus
Wells Messersmith
Professor and Cancer Center Director
University of Colorado Cancer Center
Gregory Riedlinger
Rutgers Cancer Institute of New Jersey
Christopher Lieu
Associate Professor
University of Denver
Haejin In
Professor of Surgery, Division of Surgical Oncology
Rutgers Cancer Institute of New Jersey
Adrie van Bokhoven
Associate Professor
University of Colorado
Todd Pitts
-
Robert Lentz
Assistant Professor
University of Colorado Cancer Center
Hannah Robinson
Assistant Professor
The Ohio State University Wexner Medical Center
Sunnie S. Kim
University of Colorado Anschutz Medical Campus
Susan Murphy
Assistance Professor
Rutgers Cancer Institute of New Jersey
Thais Bartelli
Research Investigator
The University of Texas MD Anderson Cancer Center
Emmanuel Dias-Neto
Visiting professor
Rutgers Cancer Institute of New Jersey
Alexis Leal
Assistant Professor of Medicine
University of Colorado Anschutz Medical Campus
Julie Lang
Associate Research Professor
University of Colorado Anschutz Medical Campus
Make your next move.
Prepare your application
Review drafts before you send them.